CSL Limited (ASX:CSL) share price up after profit jumps 29%


The CSL Limited (ASX: CSL) share price is up $2.44 or 1.21% to $204.13 in early trade after announcing a full-year net profit of $US1.73 billion ($A2.39 billion), up 29%.

The vaccines and blood products supplier said sales revenue for the year to June 30 rose 14.7% to $US7.59 billion. The results were slightly ahead of the guidance the company provided in May.

CSL also announced a final dividend of 93 US cents per share, compared to 72 US cents per share paid last year.

Profit boosted by new product launches and strong sales of flu vaccine

The company’s vaccines firm, Seqirus, broke even three years after it was formed, following a severe flu season in the United States.

Influenza vaccine sales grew 53% at current currency – which removes the impact of foreign exchange fluctuations – with doses of the vaccine quadrupled at the company’s North Carolina facility.

Sales for the FLUAD flu vaccine – for people over the age of 65 – grew by 142%.

“Seqirus delivered on its commitment to achieving profitability just three years after the business was formed,” managing director Paul Perreault said in a statement on Wednesday.

“We continue to implement process improvements to further boost this capacity.”

During the year, the company had “exceptionally strong” launches of drugs to treat haemophilia and angioedema – a hereditary condition that can cause swelling of the face, abdomen and limbs.

The company has also commenced a phase three clinical trial of CSL112, a drug, which if successful, will reduce early recurrent cardiovascular events in heart attack survivors.


The company expects 2018/19 net profit in constant currency terms to be in the range of $US1.88 billion to $US1.95 billion, an increase of 10-14%t from 2017/18.

The CSL Limited share price has gained 43% since the beginning of 2018, compared to the S&P/ASX 200 Index, which has risen 3.87%.

with AAP 

Here’s how you can strike it rich in the share market…

The best way to strike it rich in the share market is to buy shares that are not only cheap, but growing quickly.

Combining countless hours of research with over 30 years of hands-on stock market investing experience, The Capital Club’s founder Bruce Jackson has just published his definitive list of 3 Cheap and Good ASX Stocks for 2018.

Best of all, the report is absolutely free, exclusively for readers of The Capital Club.

In this comprehensive free report, you’ll find the name of one ASX gold stock that’s not only profitable, but trading at less than 4 times forecast profits.

You’ll also discover the name of a company one fund manager has called the cheapest stock in the ASX 100, and you’ll read about the three catalysts that could push the share price higher in the next six months.

Finally, the report names one of the cheapest retailers trading on the ASX, a company that just picked up the assets of a distressed competitor on the cheap, paying just 2 times earnings. No wonder one top fund manager thinks its share price could at least double.

With the share prices of each of these 3 companies having the potential to double or more, you’ll want to act now. Simply click here or the button below, enter your email address, and this free report will be instantly sent to you.

See the 3 stocks

Contributors to this article may own shares in some of the companies mentioned in this article. The Capital Club has a thorough disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
Lauren Surplice is a keen follower of the stock market, investing in individual companies and funds. She follows the daily stock market news, covering the ASX stocks that are moving the markets. You can contact Lauren at laurens@thecapitalclub.com.au